Google Ads for Research Peptides: Campaign Structure That Holds Up
Keyword strategy, negative lists, and campaign structure for research peptide suppliers, built around intent separation rather than volume.
Key takeaways
- Intent separation is the core structural decision: compound-specific research intent in one place, everything consumption-adjacent excluded.
- Negative keyword hygiene protects the account, not just the budget — the wrong query on the wrong page is a policy event.
- Start narrow enough to survive review, then widen once approval and tracking are stable.
- Brand and non-brand must be separated before any efficiency claim about the account is meaningful.
The structure we default to
Four campaign roles, launched in this order:
- Brand. Cheap, defensive, and the fastest source of clean conversion data for early bidding decisions.
- Compound-specific non-brand. One ad group per compound family, tight match types, landing on the corresponding product or category page.
- Category and comparison. Broader research and supplier-selection intent, landing on documentation-rich pages rather than product pages.
- Retargeting / retention. Only after tracking is verified, with audience exclusions for existing purchasers where relevant.
Shopping and Performance Max come later, and only once Merchant Center is stable — see Peptide Google Shopping.
Keyword selection under policy constraints
Query intent for peptides splits into three groups. Only one of them is safe to buy.
| Intent group | Examples of the pattern | Treatment |
|---|---|---|
| Supply / specification | compound + supplier, purity, COA, buy, mg, vial | Target |
| Consumption / protocol | dosage, cycle, how to inject, stack, results | Negative, site-wide |
| Medical / condition | condition names, treatment, prescription, clinic | Negative for suppliers; different account model for clinics |
Match types matter more here than in normal ecommerce. Broad match on a compound name reliably pulls consumption queries into the account within days.
Negative lists as a compliance control
Maintain shared negative lists in tiers:
- Tier 1 — policy: dosing, administration, condition, prescription, and outcome language. Non-negotiable, applied account-wide.
- Tier 2 — commercial: free, sample, wholesale-if-you-are-not-wholesale, jobs, courses, DIY.
- Tier 3 — irrelevant: unrelated compounds, lab equipment, academic paper queries.
Review search terms weekly at minimum in the first two months. The point is not only wasted spend; it is that consumption-intent traffic hitting your pages generates exactly the engagement pattern that invites review.
Bidding and ramp
With low conversion volume, aggressive Smart Bidding targets stall in learning. A practical ramp:
- Manual CPC or Maximise Clicks with a firm CPC ceiling while conversion tracking is being validated.
- Once 15–30 conversions per campaign per month are consistently recorded, move to tCPA/tROAS starting near current actuals, not at ambition.
- Change one variable at a time, with at least a full conversion cycle between changes.
Tracking accuracy is the prerequisite for all of this: see conversion tracking for peptide ecommerce.
Founder Question
“Broad match is working for our other channels. Why restrict it here?”
Our Perspective
Because in this category the wrong query isn’t just wasted spend — it is a policy signal. Broad match on compound names pulls consumption-intent traffic into the account within days, which shapes both your cost and how your account reads to review systems. Tight intent control is a compliance control here, not just an efficiency one.
Practical Recommendation
- Separate intent structurally: supply and specification terms in, consumption and condition terms excluded at account level, not ad group level.
- Build tiered policy negative lists as a standing control, and review search terms daily in the first week rather than weekly.
- Keep bidding manual or conversion-volume-appropriate at launch. Smart Bidding on a thin, unverified conversion signal amplifies whatever is wrong with your tracking.
What we learned
The pattern we keep seeing: accounts that treat negative keyword lists as a compliance control rather than a budget tool stay approved longer. Consumption-intent traffic doesn't just waste money, it shapes what your site looks like to Google.
Frequently asked
Should we bid on competitor brand names?
Usually not early. It raises scrutiny, invites complaints, and converts poorly for suppliers whose differentiator is documentation rather than price.
How narrow is too narrow at launch?
If a campaign cannot record a handful of conversions a week, it will never inform bidding. Narrow on intent, not on volume.
Can Performance Max work for research peptides?
Only with a stable Merchant Center, disciplined exclusions and mature tracking. Launching PMax first is the fastest way to buy consumption-intent traffic you cannot control.
Next step
If you want this applied to your account and your site rather than read in the abstract, book a 30-minute strategy session. We will look at the domain before the call.
Book a Strategy CallRelated articles
Can Peptide Companies Advertise on Google? (2026 Reality Check)
A straight answer on whether peptide companies can run Google Ads, which policies apply, and what separates approved accounts from suspended ones.…
Peptide Google Shopping: Feed Strategy and Campaign Structure
How to build a peptide product feed that survives review and performs, plus when Standard Shopping beats Performance Max for this category.…
Conversion Tracking for Peptide Ecommerce (Without Fooling Yourself)
A tracking build for peptide stores: single source of truth, enhanced conversions, consent handling, and the double-counting patterns that quietly bre…